Larvol Delta - Axalbion-Presented-Promising-Phase-2-Clinical-Data-in-Chronic-Cough-with-AX8-a-Novel-TRPM8-Agonist-in-an-Oral-Presentation-at-the-American-Thoracic-Society-ATS-2023-International-Conference

AX-8 - Axalbion

https://www.businesswire.com/news/home/20230522005155/en/Axalbion-Presented-Promising-Phase-2-Clinical-Data-in-Chronic-Cough-with-AX-8-a-Novel-TRPM8-Agonist-in-an-Oral-Presentation-at-the-American-Thoracic-Society-ATS-2023-International-Conference

May 22, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next